Clinical Trials Browser

spartalizumab × Genitourinary × 90 days × Clear all

Carcinoma, Renal Cell

NCT02964078 2026-04-02

Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer

Phase 2 Completed

27 enrolled 10 charts

Genitourinary

Kidney Diseases, Kidney Neoplasms, Neoplasm Metastasis

NCT03860272 2026-03-30

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Phase 1 Active not recruiting

499 enrolled

GastrointestinalGenitourinaryGynecologicSarcomaThoracic

Fibrolamellar hepatocellular carcinoma, Carcinoma, Non-Small-Cell Lung, Hemangiosarcoma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT07090148 2026-03-11

Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC

Phase 1 Recruiting

14 enrolled

Genitourinary

Prostatic Neoplasms

NCT06114940 2026-03-05

PLUTO

Phase 2 Terminated

17 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT04895748 2026-03-03

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

Phase 1 Terminated

40 enrolled

CNSEndocrineGenitourinary

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell, von Hippel-Lindau Disease, Paraganglioma, Pheochromocytoma

Clinical Trials

SPARC-1

Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC

PLUTO

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies